BioPharma « Terug naar discussie overzicht

GTCB samengevat !

311 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 ... 12 13 14 15 16 » | Laatste

Omlaag ↓

[verwijderd] 12 september 2005 12:31

Voor nieuwe belangstellenden:

Nog steeds zien wij in het 'GTCB los?' draadje herhaaldelijk de vraag hoe aandelen GTC Biotherapeutics gekocht kunnen worden bij de diverse reguliere banken. Men kan het aandeel niet vinden. Dat kan kloppen. Bij Alex, Binck of Today's Brokers (Nederlandse versie van Interactive Brokers) kan dat heel envoudig on-line (zoeken bij de G op Nasdaq).

Dames en heren, ook bij uw huisbank kunt u aandelen GTCB, aanschaffen, maar dan gewoon even bellen en uw opdracht opgeven.
De transactiekosten zijn dan wat hoger dan on-line, maar wie maalt er bij deze KANS op grote winst over die paar centjes? Datzelfde geldt ook voor de aankoopkoers. Je helpt ons allen als je gewoon op de laat koopt.

Dit is geen koopadvies, maar als je toch wilt kopen heb je hier de eenvoudigste weg.

Groet, Bidul
vol vertrouwen in de goede afloop

quote:
Snorkle schreef:
Houden jullie het nog vol jongens ?

Laatste loodjes, gewoon op de feiten blijven letten.

1) EMEA heeft de studie opgezet
2) studie resultaten waren erg goed
3) EMEA heeft nooit gevraagd aan GTC haar MAA terug te trekken
4) Zwaartepunt vragen lag niet op kritische delen
5) Downstreaming word gedaan door een van de meest bekende en grote zuiveraars van Amerika en is al FDA en EMEA approved.

Gaat goed komen, gewoon nog even geduld en niet laten gek maken.

Succes.

Groet Snorkle
[/quote]

En wanneer is het zover?

[quote=strong buy]
Data om in dit verband rekening mee te houden: de bijeenkomsten van CHMP van EMEA (Medicinal products for human use) waar Atryn mogelijk ter beoordeling wordt gesteld:

25-28 juli
22-25 aug
12-15 sept
10-12 okt

Wanneer dan het PB met de beoordeling komt, blijft natuurlijk gissen.

bron:Bikkel

sb

ludwig mack 19 september 2005 20:20

weer op de voorpagina !

[verwijderd] 19 september 2005 21:13

quote:
*BENZ schreef:
Wanneer goedkeuring? ik geloof niet in februari. Ik denk eerder aan 15 December. Zou wel een leuk kerstcadeautje zijn.

October
Date Meeting Title
10 - 13 Committee for Medicinal Products for Human Use (CHMP)

November
Date Meeting Title
14 - 17 Committee for Medicinal Products for Human Use (CHMP)

December
Date Meeting Title
12 - 15 Committee for Medicinal Products for Human Use (CHMP)

deze zullen hier nu ook niet misstaan, toch

[verwijderd] 30 september 2005 08:54

4 nieuwe patenten GTCB

www.freshpatents.com/Gtc-Biotherapeut...

[verwijderd] 30 september 2005 17:47

Mooie posting lucide
Ik plaats hem ook even in GTCB LOS draadje
Groet

quote:
De Lucide schreef:
4 nieuwe patenten GTCB

www.freshpatents.com/Gtc-Biotherapeut...

[verwijderd] 5 oktober 2005 10:53

En weer naar boven.

Grtz Ducatist

[verwijderd] 5 oktober 2005 10:54

En weer naar boven.

Grtz Ducatist

[verwijderd] 5 oktober 2005 10:54

En weer naar boven.

Grtz Ducatist

[verwijderd] 5 oktober 2005 10:55

En weer naar boven.

Grtz Ducatist

$rob$ 5 oktober 2005 11:00

4 patenten erbij, koers naar beneden, tja.....

[verwijderd] 5 oktober 2005 11:29

Das 4 x nou ja beter dan het te laten versloeberen onder in de kast.

Grtz Ducatist

[verwijderd] 5 oktober 2005 12:14

Webcast:

www.tinyurl.com/ds4an

Groet,

Songh.

ludwig mack 10 oktober 2005 20:11

up !

[verwijderd] 10 oktober 2005 20:19

7 November bij Rodman & Renshaw

www.rodmanandrenshaw.com/rodman.asp?l...

12:20 uur GTCB

positivo73 18 oktober 2005 16:46

klein schopje

ludwig mack 21 oktober 2005 15:55

www.gtc-bio.com/news.html

[verwijderd] 21 oktober 2005 17:23

Slecht nieuws, althans tijdelijk kans op lagere prijs per aandeel en verwatering:

GTC BIOTHERAPEUTICS ANNOUNCES FILING OF SHELF REGISTRATION STATEMENT

FRAMINGHAM, MA – October 21, 2005 -- GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) announced today that it has filed a universal shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission ( SEC) pursuant to which the Company may issue up to an aggregate of $50 million of common stock, debt securities, and other types of securities. Proceeds from any offering under the shelf registration statement would provide flexibility in financing GTC’s business needs, including funding for development and commercialization of its products and clinical programs as well as for general corporate purposes. The terms and price of any future offerings would be established at the time of the offering.

The shelf registration statement, when declared effective by the SEC, would enable GTC to raise funds from the offering of stock and debt securities covered by the shelf registration statement from time to time and through one or more methods of distribution, subject to market conditions and GTC’s capital needs.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

A copy of the preliminary prospectus included in the registration statement may be obtained at the SEC's website at www.sec.gov, through the Investor Relations section of the GTC website at www.gtc-bio.com or via written request to GTC Biotherapeutics, 175 Crossing Blvd., Framingham, MA 01702, Attention: Investor Relations.

GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATryn®, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn® in patients with a hereditary antithrombin deficiency. In addition to the lead ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. Additional information is available on the GTC web site, www.gtc-bio.com.

CONTACT:
GTC Biotherapeutics, Inc.
Thomas E. Newberry
Vice President, Corporate Communications
US (508) 370-5374

Feinstein Kean Healthcare for GTC Biotherapeutics, Inc.
Francesca DeVellis
US (617) 577-8110

If you wish to be removed from this distribution list, please reply to this email with "REMOVE" in the subject line.

[verwijderd] 21 oktober 2005 20:17

GTC BIOTHERAPEUTICS TO WEBCAST CORPORATE PRESENTATION AT CEUT EMERGING GROWTH LIFE SCIENCES CONFERENCEFRAMINGHAM, MA, October 21, 2005—GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) announced today that Geoffrey Cox, Ph.D., Chairman and CEO of the Company, is scheduled to present an update on GTC's product and corporate development on Wednesday, October 26, 2005 at 9:00 a.m. during the CEUT Emerging Growth Life Sciences Conference. The conference is being held at the
Palace Hotel in New York, October 25-26, 2005.

The presentation will be webcast live and can be accessed by logging onto www.gtc-bio.com <http://www.gtc-bio.com/>. The replay can be accessed from this same website and will be available within 24 hours of the presentation.

GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATryn®, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn® in patients with a
hereditary antithrombin deficiency. In addition to the lead ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are
difficult to produce in significant quantities from conventional recombinant production systems. Additional information is available on the GTC web site, www.gtc-bio.com <http://www.gtc-bio.com/>.
CONTACT:GTC Biotherapeutics, Inc.Thomas E. NewberryVice President, Corporate CommunicationsUS (508) 370-5374

Feinstein Kean Healthcare for GTC Biotherapeutics, Inc.Francesca DeVellis US (617) 577-8110

If you wish to be removed from this distribution list, please reply to this email with "REMOVE" in the subject line.

[verwijderd] 24 oktober 2005 09:54

Update

www.investorshub.com/boards/read_msg....

ludwig mack 27 oktober 2005 15:56

voorpagina

311 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 ... 12 13 14 15 16 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 878,00 -4,27 -0,48% 17:14


Germany40^	17.920,80	-1,09%
BEL 20	3.881,27	-0,14%
Europe50^	4.916,14	-1,30%
US30^	38.187,95	-0,47%
Nasd100^	17.631,29	-0,89%
US500^	5.078,57	-0,71%
Japan225^	38.453,54	+0,60%
Gold spot	2.296,42	-1,69%
EUR/USD	1,0690	-0,29%
WTI	81,78	-1,11%